DUBLIN–(BUSINESS WIRE)–The “Global Cryptococcosis Treatment Market (2021-2026) byTreatment, Distribution Channel, Geography and the Impact of COVID-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
Cryptococcosis or cryptococcal disease is basically a fungal disease, which can prove to be fatal in severe cases. It occurs due to inhalation of fungus associated with bird species. It can affect the humans leading to meningitis in several cases. The occurrence of this disease is increasing beyond years due to the rise in the number of diseases especially prevalent in the emerging economies.
Certain infections like HIV which lead to a weak immune system as well as the extended use of immunosuppressive drugs are supporting the growth of this market. Alternatively, lack of efficient diagnostic tools and trials to prevent this infection are digressing the growth of this market.
The Global Cryptococcosis Treatment Market is estimated to be USD 4.8 Bn in 2021 and is expected to reach USD 6 Bn by 2026 growing at a CAGR of 4.5%.
Segments Covered
By Geography, North America leads the market. The Global Cryptococcossis market can be segmented on the basis of treatment, distribution channel and geography.
Global Cryptococcosis Treatment Market, By Treatment
- Introduction
- Amphotericin B
- Amphocin
- Fungizone
- Others
- Fluconazole
- Diflucan
- Others
- Flucytosine
- Ancobon
- Others
- Others (Voriconazole, Surgery Treatment, etc.)
Global Cryptococcosis Treatment Market, By Distribution Channel
- Introduction
- Hospital Pharmacies
- Mail Order Pharmacies
- Retail Pharmacies & Drug Stores
Global Cryptococcosis Treatment Market, By Geography
- North America
- South America
- Europe
- Asia Pacific
- Middle East and Africa
Competitive Quadrant
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share etc.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Cryptococcosis Market.
- The report includes in-depth qualitative analysis, verifiable data from authentic sources and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using Competitive Quadrant, the analyst’s proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Market Dynamics
Drivers
- The growing incidence of cryptococcosis infections
- Increasing incidence of fatal fungal infections
- Increasing availability of generic and over-the-counter (OTC) medicines
Restraints
- Reduced scope of testing and diagnostics due to increased mortality among cryptococcosis infected patients
- Limited clinical awareness in patients
- Lack of skilled technicians
Opportunities
- Drug development and evolving clinical trial ecosystem
- Initiatives undertaken by the government, NGOs, and the healthcare providers
Companies Mentioned
- Bristol-Myers Squibb Company
- Janssen Biotech, Inc. (Johnson & Johnson)
- Abbott Laboratories
- Novartis AG
- Pfizer, Inc.
- Valeant Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals
- Viamet Pharmaceuticals, Inc.
- Sigmapharm Laboratories LLC
- Astellas Pharma Inc.
- Bausch Health Companies Inc.
- Matinas BioPharma
- NuCare Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/m3tofs
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900